The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer

Adjuvant chemotherapy for colon cancer (UICC stage II and III) has been under investigation over the last 30 years, regarding treatment duration and regimens. In this review, choice of regimen, its duration, possible limitations and future perspectives are discussed. Monotherapy with 5-fluorouracil...

Full description

Bibliographic Details
Main Authors:	Maike Collienne, Dirk Arnold
Format:	Article
Language:	English
Published:	MDPI AG 2020-09-01
Series:	Cancers
Subjects:	colon cancer adjuvant therapy peripheral sensory neurotoxicity
Online Access:	https://www.mdpi.com/2072-6694/12/9/2509

Similar Items

Adjuvant Chemotherapy for Stage III Colon Cancer
by: Julien Taieb, et al.
Published: (2020-09-01)

Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study
by: Tsuruta A, et al.
Published: (2016-11-01)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
by: Colin Sue-Chue-Lam, et al.
Published: (2023-07-01)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
by: Huabin Hu, et al.
Published: (2020-12-01)

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
by: Po-Huang Chen, et al.
Published: (2022-12-01)

Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients
by: Hyun Jin Bang, et al.
Published: (2022-05-01)

The Prognostic Value of Adjuvant Chemotherapy in Colon Cancer With Solitary Tumor Deposit
by: Qiangkang Lin, et al.
Published: (2022-07-01)

Adjuvant Chemotherapy for Stage II Colon Cancer
by: Sara Elena Rebuzzi, et al.
Published: (2020-09-01)

Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial
by: Yoshimura Kenichi, et al.
Published: (2013-01-01)

Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration
by: Renfro Lindsay A., et al.
Published: (2014-12-01)

Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer
by: Kabytto Chen, et al.
Published: (2022-02-01)

Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
by: Jung Minkyu, et al.
Published: (2012-10-01)

Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients
by: Eiji Oki, et al.
Published: (2021-12-01)

Wheatgrass Juice Administration and Immune Measures during Adjuvant Chemotherapy in Colon Cancer Patients: Preliminary Results
by: Adva Avisar, et al.
Published: (2020-06-01)

Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients
by: Linjie Zhang, et al.
Published: (2023-01-01)

The effect of smoking, obesity and diabetes on recurrence‐free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy
by: Alex Croese, et al.
Published: (2021-06-01)

Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study
by: Jankova Lucy, et al.
Published: (2012-05-01)

Real-life experiences and barriers to adjuvant chemotherapy in Saudi patients with advanced stage II and stage III colon cancer
by: Mesnad S Alyabsi, et al.
Published: (2024-01-01)

Recurrence‐free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials
by: Emma Vail, et al.
Published: (2024-01-01)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
by: Sarah Xinhui Tan, et al.
Published: (2023-07-01)

Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health system
by: Yan Lu, et al.
Published: (2022-05-01)

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study
by: Elizabeth Alwers, et al.
Published: (2020-02-01)

Survival and time interval from surgery to the start of chemotherapy for patients with stage II and III colon cancer
by: Denis Ganenko, et al.
Published: (2019-01-01)

Extracellular Vesicles Reflect the Efficacy of Wheatgrass Juice Supplement in Colon Cancer Patients During Adjuvant Chemotherapy
by: Adva Avisar, et al.
Published: (2020-08-01)

Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection
by: Peng J, et al.
Published: (2018-07-01)

The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis
by: Daniel Breadner, et al.
Published: (2022-11-01)

CXCR6+ Tumor-Associated Macrophages Identify Immunosuppressive Colon Cancer Patients with Poor Prognosis but Favorable Response to Adjuvant Chemotherapy
by: Jiang Chang, et al.
Published: (2022-09-01)

Perineural Invasion Is a Strong Prognostic Factor but Not a Predictive Factor of Response to Adjuvant Chemotherapy in Node-Negative Colon Cancer
by: Junhao Tu, et al.
Published: (2021-03-01)

Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
by: Angela Mauriello, et al.
Published: (2020-01-01)

The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
by: Leen Liao, et al.
Published: (2024-02-01)

Postoperative Adjuvant Chemotherapy Regimen of CAPOX Combined With Ninjin'yoeito in an Elderly Patient With Stage III Colon Cancer: A Case Report
by: Naoki Aomatsu, et al.
Published: (2020-04-01)

Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study
by: Kexuan Li, et al.
Published: (2023-09-01)

The Impact of Colon Cancer Sites on Survival Rates after Curative Resection and Adjuvant Chemotherapy: A SingleCenter Study
by: Sureerat Jaruhathai, et al.
Published: (2022-10-01)

Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study
by: Hongjiang Pu, et al.
Published: (2024-03-01)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
by: Peng Gao, et al.
Published: (2018-03-01)

Dietary Supplements in Chemotherapy-Induced Peripheral Neuropathy: A New Hope?
by: Katarzyna Szklener, et al.
Published: (2022-01-01)

Gait analysis in chemotherapy-induced peripheral neurotoxicity rodent models
by: Maria Lopez-Garzon, et al.
Published: (2023-10-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
by: Timothée Olivier, et al.
Published: (2023-09-01)